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Abstract: Genetically-engineered mouse models (GEMMs) lacking diseased-associated gene(s)
globally or in a tissue-specific manner represent an attractive tool with which to assess the efficacy
and toxicity of targeted pharmacological inhibitors. Stat3 and Stat5a/b transcription factors have
been implicated in several pathophysiological conditions, and pharmacological inhibition of both
transcription factors has been proposed to treat certain diseases, such as malignancies. To model
combined inhibition of Stat3 and Stat5a/b we have developed a GEMM harboring a flox Stat3-Stat5a/b
allele (Stat5/3loxP/loxP mice) and generated mice lackingStat3 andStat5a/b in hepatocytes (Stat5/3∆hep/∆hep).
Stat5/3∆hep/∆hep mice exhibited a marked reduction of STAT3, STAT5A and STAT5B proteins in the liver
and developed steatosis, a phenotype that resembles mice lacking Stat5a/b in hepatocytes. In addition,
embryonic deletion of Stat3 and Stat5a/b (Stat5/3∆/∆ mice) resulted in lethality, similar to Stat3∆/∆ mice.
This data illustrates that Stat5/3loxP/loxP mice are functional and can be used as a valuable tool to model
the combined inhibition of Stat3 and Stat5a/b in tumorigenesis and other diseases.
Keywords: bacterial artificial chromosome; recombineering; Cre/loxP; gene targeting; embryonic
stem cells; liver steatosis
1. Introduction
Genetically-engineered mouse models (GEMMs) lacking gene(s) of interest in the whole animal
or in a tissue-specific manner offer a unique opportunity to model the effects of pharmacological
inhibitors, as well as to assess toxicity in models of health and disease [1]. Upon identification of a
cancer target gene(s), the toxicity and efficacy of future inhibitors can be evaluated by crossing mice
harboring alleles of interest flanked by loxP sites (flox mice) with tissue-specific and inducible Cre
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recombinase expressing mouse strains and deleting the gene(s) in appropriate cancer-mouse models [2].
This strategy offers a straight forward and rigorous method for target validation before undertaking
costly and time-consuming development of antitumorigenic targeted inhibitors.
Signal transducer and activator of transcription family members (STAT1, 2, 3, 4, 5A, 5B and 6)
are transcription factors which are activated in response to multiple cytokines and growth factors.
The binding of ligands to their cognate receptors results in the activation of Janus kinase (JAK) family
members (JAK1, 2, 3 and Tyrosine kinase 2, TYK2). Tyrosine phosphorylation of STATs by JAK
family members induces homo- and hetero- dimerization, as well as subsequent translocation into the
nucleus where STAT proteins bind to their specific DNA sequences and control the transcription of
multiple genes [3,4]. STAT3, STAT5A and STAT5B have been implicated in several physiological and
disease processes such as cell division, migration, survival, cellular responses to pathogens, breast
development, inflammation and cancer [5]. Indeed, the over-activation of STAT3 and STAT5A/B has
been reported in human hematopoietic and solid malignancies, suggesting that these transcription
factors behave as oncogenic drivers in those tumors [6,7]. These observations have been complemented
with functional studies using GEMMs harboring flox alleles for Stat3 [8–13] and Stat5a/b [14] genes.
Consequently, several research groups have developed inhibitors targeting STAT3 or STAT5A/B to treat
malignancies [6]. Unfortunately, monotherapy treatment of tumors almost invariably results in tumor
resistance. Tumor cells acquire resistance to drugs by (re)activating alternative or redundant signaling
pathways [15]. STAT3 and STAT5A/B have overlapping functions in several (patho)physiological
contexts [16–19]; thus it is expected that tumor cells will acquire resistance to single inhibitors by
compensatory mechanisms relaying in the activation of the non-inhibited STAT family member.
Therefore, dual inhibitors targeting both STAT3 and STAT5A/B or a combination of single STAT3 and
STAT5A/B inhibitors may be more effective [20], albeit perhaps also resulting in increased toxicity. Stat3,
Stat5a and Stat5b are genetically-linked genes, clustering within a 160 kb genomic region of mouse
chromosome 11. This should preclude modeling simultaneous inhibition of STAT3 and STAT5A/B
simply by intercrossing Stat3 and Stat5a/b single flox mice. To overcome this issue, we have generated a
new GEMM which contains an allele harboring the Stat3, Stat5a and Stat5b genes flanked by loxP sites
(Stat5/3loxP/loxP mice). Stat5/3loxP/loxP mice crossed to a transgenic line expressing the Cre recombinase in
hepatocytes showed deletion of STAT3 and STAT5A/B in the liver and developed steatosis at the age of
eight weeks. Furthermore, embryonic deletion of STAT3 and STAT5A/B resulted in a lethal phenotype.
This demonstrates that the Stat5/3loxP/loxP mouse is functional and can be readily used to model STAT3
and STAT5A/B double inhibition in cancer and other disease-experimental mouse models.
2. Results and Discussion
2.1. Generation of Stat3 and Stat5a/b Flox (Stat5/3loxP/loxP) Mice
A Bacterial Artificial Chromosome (BAC)-based targeting construct [21,22] spanning the Stat3,
Stat5a and Stat5b locus was generated as follows: a 200 kb BAC (BAC, RPCI-23-362J7) (Figure 1A
and Supplementary Figure S1) was modified by introducing a loxP-FRT3-Neomycin-FRT3 cassette
using BAC homologous recombination [23] upstream of the Stat5b gene as previously described [14].
In a second recombination step, a FRT-Hygromycin-FRT-loxP cassette was introduced within the first
intron of the Stat3 gene between exons 1 and 2. Stat3 exon 2 contains the ATG translation initiation
codon; thus, the flox strategy predicts the absence of a STAT3 truncated protein (Supplementary
Figure S1). The BAC-based targeting construct was linearized using the restriction enzyme Not I
and electroporated into HM-1 mouse embryonic stem cells (ES, 129/ola origin [24]). Out of around
thirty ES cell clones which survived the neomycin/hygromycin double selection, eighteen appeared to
have an undifferentiated morphology and were chosen for further analysis. We performed Southern
blot analysis of genomic DNA derived from the selected clones using a DNA probe upstream of
the hygromycin cassette to visualize the endogenous (wt) and the transgenic alleles (Figure 1B).
We presumed that equal intensities of wt and transgene bands either indicated correctly targeted ES
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cells which had incorporated the transgene in the endogenous Stat5/3 locus or random integration of
two copies of the transgene. Unequal intensities between the wt and transgene bands would suggest
random integration of the transgene into the genome. Clones 9, 10, 11, 13 and 15 (Figure 1B) showed
wt and transgene bands of approximately equal intensities and were further evaluated.
Figure 1. Conditional targeting the Stat5a, Stat5b and Stat3 loci. (A) ES cells targeting strategy. A BAC
spanning the Stat5a/b and Stat3 loci was modified by introducing a neomycin resistance cassette flanked
by FRT3 sites and containing a 5′loxP site upstream of the Stat5b locus. In a second recombineering step,
a hygromycin resistance cassette flanked by two FRT sites and containing a 3′loxP site was introduced
in the first intron of the Stat3 locus (depicted as a dotted line), thus floxing the entire coding regions of
the Stat5a, Stat5b and Stat3 genes. (B) Southern blot analysis using EcoRI-digested genomic DNA from
neomycin/hygromycin resistant ES cell clones and a probe localized 3′ downstream of the hygromycin
cassette identified a band corresponding to the endogenous locus (wt, upper band) and the transgene
(lower band). ES cell clones labeled with a star (9, 10, 11, 13 and 15) show roughly equal wt and
transgene band intensities suggesting a correct targeting event or a random integration of two extra
transgenic copies into the genome.
We performed Fluorescence In Situ Hybridization (FISH) using the RPCI-23-362J7 BAC as probe
for the selected clones (Figure 2A and Table 1). wt ES cells showed mainly two signals, but we also
observed nuclei containing three signals, suggesting chromosomal abnormalities. Notably, mouse ES
cells tend to harbor a trisomy of chromosome 11 [25], which harbors the Stat5/3 locus. Clone 8 (which
was included in the analysis as a control because the transgene band showed a higher intensity than
the wt in the Southern blot, indicating a random integration event) displayed three signals. Clones
10, 11, 13 and 15 also showed mainly three or four signals (Table 1), suggesting that the transgene
had been randomly incorporated into the genome of these clones. In contrast, clone 9 exhibited two
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signals, indicating correct recombination of the transgene into the endogenous locus. Furthermore,
PCR analysis of genomic DNA showed that the 5′ and 3′ ends of the BAC construct were not present in
clone 9, demonstrating that they were lost during homologous recombination (Figure 2B). Additionally,
genomic qPCR using three pairs of primers flanking either the neomycin cassette (P3 and P4), a central
region in the Stat5a locus (P5 and P6) or the hygromycin cassette (P7 and P8) confirmed that clone
9 contained one copy of the wt endogenous Stat5/3 locus and one copy of the transgene (Figure 2C).
Of note, primers P3/P4 and P7/8 do not amplify the transgenic construct. Finally, the functionality of
the loxP sites was assessed by transfecting a plasmid expressing the Cre recombinase [26] into clone
9. Indeed, deletion of the Stat5/3 locus was achieved as demonstrated by PCR using genomic DNA
and primers P9 and P10 (Figure 2D). Therefore, we used ES cell clone 9 for the generation of chimeric
animals via injection of the ES cell clone into blastocysts. Subsequently, these mice were mated to
C57BL/6N mice to establish a mouse line harboring the Stat5/3loxp allele.
Figure 2. Identification of correctly targeted ES cells. (A) FISH analysis of wt ES cells and clones 8 and
9 using the RPCI-23-362J7 BAC as a probe showing that clone 9 has undergone correct homologous
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recombination. Upper pictures: representative interphase nuclei. Lower pictures: representative
metaphases. Red arrows: endogenous locus, blue arrow: ectopic transgene integration. (B) PCR
analysis using primers (P1/Sp6 and P2/T7), which amplify the ends of the BAC-based targeting construct,
fails to detect the presence of BAC-ends in ES cell clone 9. +: BAC DNA (positive control). −: wt ES
cell DNA (negative control) LC: loading control. (C) Quantitative PCR using primer pairs (P3/P4, P5/P6
and P7/8) spanning the Stat5a/b and Stat3 loci shows that ES cell clone 9 harbors one copy of the Stat5a/b
and Stat3 endogenous locus and one copy of transgene in its genome (of note, primers P3/P4 and P7/8
do not amplify the transgenic construct). (D) PCR analysis (primers P9/P10) of genomic DNA from ES
cell clone 9 electroporated with a plasmid expressing the Cre recombinase shows a specific product
confirming the functionality of the loxP sites. LC: loading control.
Table 1. Quantification of the FISH analysis performed in the ES cell clones. FISH was performed
using the RPCI-23-362J7 BAC as a probe in wildtype (wt) ES cells and clones 8, 9, 10, 11, 13 and 15.
The result is expressed as the percentage of interphases (two hundred analyzed) containing one, two,
three or four signals.
% of Cell Interphases
ES Clone One Signal Two Signals Three Signals Four Signals
wt 1.5 73.0 20.5 5.0
8 0.0 9.0 85.0 6.0
9 4.5 93.5 2.0 0.0
10 0.0 3.0 27.5 69.5
11 0.0 4.0 83.5 12.5
13 0.0 11.0 80.0 9.0
15 0.0 1.0 29.0 70.0
2.2. Functional Validation of Stat5/3loxP/loxP Mice
Stat5/3loxP/loxP mice are viable; genotyping shows that they are born at Mendelian ratio (Figure 3A
and Table 2) and do not exhibit any obvious phenotype. Stat5/3loxP/loxP mice (backcrossed five
generations into C57BL/6N) were crossed to a transgenic line expressing the Cre recombinase under
control of the Actb promoter [27] to obtain a null allele (Stat5/3∆/+ mice). Intercrossing of Stat5/3∆/+
mice did result in viable Stat5/3∆/∆ blastocysts, but not in living offspring (Table 2), suggesting that
Stat5/3∆/∆ mice were embryonic lethal, as previously described for Stat3∆/∆ mice [28].
Table 2. Genotype distribution of Stat5/3 wt, heterozygote and homozygote animals. Number of
embryos and pups from Stat5/3∆/+ × Stat5/3∆/+ breeding distributed accordingly to the genotype
(expected number in brackets). Statistical differences from the expected numbers were analysed with
the chi-square test using GraphPad QuickCalcs.
Genotype
Stage Stat5/3+/+ Stat5/3∆//+ Stat5/3∆/∆ p Value
Blastocysts 8 (9) 23 (18) 5 (9) 0.1942
Born mice 22 (12) 27 (25) 0 (12) <0.0001
Previous reports have shown that the deletion of Stat5a/b in hepatocytes results in liver steatosis [29].
Therefore, we investigated the effect of concomitant Stat5a/b and Stat3 deletion in the liver. Stat5/3loxP/loxP
mice were intercrossed with transgenic mice expressing the Cre recombinase under the control of the
tetO promoter (tetO-Cre mice [30]) and with mice expressing the tetracycline-controlled transactivator
(tTA) in hepatocytes from the liver-enriched activator protein promoter (LAP-tTA mice [31]) to obtain
triple transgenic animals: Stat5/3loxP/loxP; LAP-tTA; tetO-Cre (hereby Stat5/3∆hep/∆hep mice, ∆hep: deleted
in hepatocytes). Liver-specific deletion of the Stat5/3 locus was confirmed by PCR using genomic DNA
from different organs of Stat5/3∆hep/∆hep mice (Figure 3B). Furthermore, Western blot analysis revealed
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that STAT5A/B and STAT3 proteins were absent in livers of Stat5/3∆hep/∆hep mice (Figure 3C). At the
macroscopic level, Stat5/3∆hep/∆hep mouse livers were enlarged and pale, suggesting lipid accumulation
(Figure 3D). HE-stained sections from livers of Stat5/3∆hep/∆hep mice confirmed a steatotic phenotype.
Taken together, these results prove that Stat5/3loxP/loxP mice are functional and recapitulate the liver
steatotic phenotype found in mice lacking Stat5a/b in hepatocytes [29].
Figure 3. Validation of Stat5/3loxP/loxP mice. (A) PCR analysis of tail DNA using the primers P9/P11/P12
and P10/P13/P14 located in the region of the neomycin and hygromycin cassettes, respectively, showing
the expected genotypes. (B) PCR analysis of genomic DNA extracted from different tissues revealed that
the Stat5a/b and Stat3 loci are deleted solely in the liver of Stat5/3∆hep/∆hep mice (Liv: liver; Kid: kidney;
Int: small intestine; Pan: pancreas; Lun: Lung; Hea: heart). (C) Western blot analysis using liver lysates
from Stat5/3loxP/loxP and Stat5/3∆hep/∆hep mice shows reduced levels of STAT5A/B and STAT3 protein in
the livers of Stat5/3∆hep/∆hep mice (HSC70: Heat Shock 70 kDa protein, loading control). Details can be
found in Figure S2. (D) Stat5/3∆hep/∆hep mice develop liver steatosis. Upper pictures: representative
macroscopic liver images of control and Stat5/3∆hep/∆hep mice. Lower pictures: representative liver
sections from 8-week-old control and Stat5/3∆hep/∆hep mice (n = 3) stained with hematoxylin and eosin
(HE), scale bar: 50 µm.
Modeling STAT3 and STAT5A/B double inhibition using GEMM in cancer and other diseases is
an attractive strategy to assess inhibitor efficacy and side effects. Stat5a/b and Stat3 are genetically
linked and located within an approximately 160 kb region of the mouse genome. Consequently,
combined deletion of Stat5a/b and Stat3 by breeding currently-available mice harboring conditional
alleles for Stat5a/b and Stat3 would be a challenging task. On the other hand, Singireddy and colleagues
have reported the generation of double Stat5a/b and Stat3 flox mice by breeding individual flox mice;
they found that double Stat5a/b and Stat3 flox mice were born at expected Mendelian ratios [32].
This may indicate that the Stat5a/b and Stat3 genomic region harbors a meiotic recombination hotspot
whose efficiency could be genetic background-dependent [33]. We have used a different approach
and generated a new transgenic mouse line carrying the Stat5a, Stat5b and Stat3 genes flanked by
loxP sites. We have used a BAC-based targeting construct to modify ES cells [21,22]. This strategy
has the advantage to flox relatively large genomic regions with one single targeting event in ES cells.
Consequently, in contrast to the Southern blot strategy used for the detection of conventional targeting
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constructs [34], correctly targeted ES cells need to be identified by FISH and/or quantification of the
endogenous and the transgenic alleles by qPCR [22]. Since Stat5/3loxP/loxP mice were generated using
ES derived from the 129/ola strain, we backcrossed these mice for five generations into C57BL/6N,
a widely-used experimental mouse genetic background. Nevertheless, it is expected that the genomic
region around the Stat5a/b and Stat3 genes is flanked by 129/ola ES cell derived DNA. This 129/ola
genomic region may contain mutations that confound the interpretation of the phenotypes found
upon the loss of Stat5a/b and Stat3 genes [35]. This issue could be overcome by generating the mice
directly in C57BL/6N-derived ES cells [36]. It is known that increased distances between the loxP sites
have been correlated with lower recombination efficiency [37]. Therefore, we aimed to demonstrate
the functionality of Stat5/3loxP/loxP mice by deleting the flox region in hepatocytes. Indeed, despite the
relatively large genomic region (135 kb) flanked by loxP sites, we were able to achieve an efficient
deletion of the Stat5a/b and Stat3 genes using a mouse line expressing the Cre recombinase in the liver
under the control of the tetracycline-transactivator [30,31]. However, other Cre transgenic lines may
not be that efficient. In this sense, crossing Stat5/3loxP/loxP mice with Alfp Cre mice (a transgenic line
which expresses the Cre recombinase in hepatocytes and cholangiocytes starting at embryonic day
9.5) [38] resulted in incomplete recombination.
Although loss-of-function approaches using knockout mice may serve to validate targets on
oncology, it has also some disadvantages. Due to the redundancy in biology, upon gene deletion,
it is not usual that other proteins with similar functions become activated, resulting in compensatory
mechanisms which may confound the interpretation phenotype [39]. In this sense, it has been reported
that deletion of Stat5a/b (but not Stat3) in hepatocytes results in liver steatosis [29], possibly due to an
unphysiological activation of STAT3 as cellular response to the lack of STAT5/B. Interestingly, in our
model, the deletion of Stat5a/b and Stat3 in hepatocytes results in liver steatosis. This finding not only
validates the functionality of our mouse model, but also suggests that the steatotic phenotype observed
upon deletion of Stat5a/b in hepatocytes is not caused by aberrant-activation/regulation of Stat3.
3. Material and Methods
3.1. BAC Recombineering
E. coli DH10B bacteria harboring the RPCI-23-362J7 BAC (purchased from CHORI) were
electroporated with the pSC101-BAD-abgA plasmid [40] and grown at 30 ◦C until the OD reached
0.2. L-Arabinose was then added to the culture (0.2% final concentration) and cells were shifted
to 37 ◦C until the OD reached 0.5. Cells were harvested and electrocompetent cells were prepared.
A neomycin/kanamycin selection cassette flanked by FRT3 sites and harboring a 5′ loxP site was
recombined in the BAC upstream of Stat5b by electroporating a DpnI-digested PCR product amplified
from a PGK/Tn5-neomycin cassette [41] using the following primers: CCAGAGAACCTGTGGGCAA
TGGAATGGGCAGAAGCCTCAACCTACACTGCATAACTTCGTATAATGTATGCTATACGAAGTTAT
GAAGTTCCTATACTATTTGAAGAATAGGAACTTCGTGGAGTCGAGGAATTCTACC and TGAGA
GGAAAGCATGAAAGGGTTGGAGCCAGGGCATTATGTGTGAGGCAGGAAGTTCCTATTCTTCAAA
TAGTATAGGAACTTCCAAAAACCAACACACAGATCATG (Italics: homology region to the BAC,
bold: loxP site, underlined: FRT3 site). Putative recombinant clones were selected using kanamycin
(25 µg/mL). Correctly recombined BACs were validated by PCR and direct BAC sequencing. In a
second round of recombineering, a hygromycin selection cassette flanked by FRT sites harboring
a 3′ loxP site was recombined into the BAC containing the neomycin/kanamycin resistance
cassette by electroporating a Dpn I-digested PCR product amplified from a pUBC/EM7-hygromicin
plasmid [42] using the following primers: GTCTGTAACTCAAGAGGCTTGTTTCAGTGTTGATGTT
TGGTGTATTTCGCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCGGCCTCCGCGCCGGGTTT
TGGC and GTTCTTGATGGTCCAGTTAATTGGAAAAAGGCACAAGCTGGTCTCTGGTTATAACTTCG
TATAGCATACATTATACGAAGTTATGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCCCTGC
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AACATGAATATTAGAA (Italics: homology region to the BAC, bold: loxP site, underlined: FRT site).
Recombined BACs were selected in kanamycin (25 µg/mL) and hygromycin (50 µg/mL).
3.2. ES Cell Targeting
First, 30 µg of the BAC-based targeting construct were digested with NotI, phenol-chloroform
extracted, ethanol precipitated, resuspended in 30 µl of PBS and electroporated into HM-1 mouse
embryonic stem cells [24] with a BioRad Gene Pulser (230 V, 500 µF). Two days after electroporation,
ES cells were selected in neomycin (350 µg/mL) and hygromycin (160 µg/mL) until colonies appeared
(7–10 days). ES cell colonies with normal morphologies were picked in 96-well plates, expanded and
transgene copy number was estimated by Southern blot using a probe located 3′ downstream of the
hygromycin cassette, which detects both the wt and transgene alleles
3.3. FISH Analysis of ES Clones
FISH was essentially performed as previously described [43]. In brief, BAC RPCI-23-362J7 DNA was
labeled with digoxigenin-11-dUTP (Roche, Basel, Switzerland) by nick translation and for the detection
of the probe sheep anti-digoxigenin-fluorescein isothiocyanate (FITC; Roche, Basel, Switzerland) and
donkey anti-sheep-FITC (Dianova #713-095-147; Jackson Immuno Research, Cambridgeshire, UK)
antibodies were used. Two hundred interphase nuclei per ES cell clone were scored for the number of
FISH signals.
3.4. Quantitative Genomic PCR
Quantitative polymerase chain reaction (qPCR) was performed using the SYBR green method
with 500 ng of genomic DNA isolated from ES cells, using the primers described in Figure 2C and
Table 3. Genomic DNA levels were normalized for the murine Rosa26 gene and relative genomic DNA
abundance was calculated using the ∆Ct (threshold concentration) method.
Table 3. List of additional primers used in this study.
Primer 5′-3′Sequence
P1 CATCATACACTTCATTTTAGGACTGCC
P2 TGGCCCAGTGTTCAGTGCTCTTCTTACC
P3 GGGACTCTTAAAATGGAAATCTGG
P4 CAGAATGTTCTAGAAGGTTTGG
P5 GTGCATGCTTTGTAGGAATTCTATGG
P6 GTGGTTCCTCTGGTTTGTTACGTAGG
P7 ATCTTGGACACAAATGCAGAGCC
P8 CTGGTTAAGAAAAAGCCATTCTACC
P9 GCTTTGAAGCTTCATCCCTATCC
P10 TAGCTTAGGATAATTTTCTTCATG
P11 GGTTGGCGCCTACCGGTGGATGTGG
P12 CAGTAGCCCAGTGTCCCAGCCAAACAG
P13 AATCAGTAATAAGTGATGATAGAAGGG
P14 CAGATGACCACTCCAGTCGGGGG
P15 ACCAGCCAGCTATCAACTCG
P16 TTACATTGGTCCAGCCACC
P17 TCTGAGCATGGCCTCTAA
P18 GCTGGAGTAAATTTCACAGTG
P19 TCTCACTCGGAAGGACAT
Sp6 GATTTAGGTGACACTATAG
T7 GTAATACGACTCACTATAGGGC
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3.5. Animals
Stat5/3loxP/loxP mice (backcrossed five generation into C57BL/6N, purchased from Charles River,
Wilmington, MA, USA), tetO-Cre mice (C57BL/6N) [30] and LAP-tTA mice (C57BL/6N) [31] were
genotyped using primers P9/P11/P12, P15/P16 and P17/P18/P19, respectively. Experiments were
performed using eight-week-old male mice. Mice were kept at the Decentralized Biomedical Facilities,
Medical University of Vienna, under standardized conditions, and all animal experiments were
carried out according to an ethical animal license protocol and contract approved by the Medical
University of Vienna and Austrian Federal Ministry of Science, Research and Economy authorities
(BMWF-66.009/0280-II/3b/2012). Stat5/3loxP/loxP strain will be available upon request.
Stat5/3∆/+ mice were generated by crossing Stat5/3loxP/loxP mice (backcrossed five generation into
C57BL/6N) with mice expressing Cre recombinase under control of the Actb promoter [27], which were
obtained from the Jackson laboratory (stock no. 003376) and back-crossed to C57BL/6N. Subsequently,
the Actb-Cre transgene was removed by backcrossing with wt C57BL/6N mice.
Blastocyst isolation was performed by superovulation and mating of heterozygous Stat5/3∆/+
females and males. Blastocysts were flushed from oviducts and uterus horns on E3.5 and cultured
in M16 in an incubator for 24 h. DNA was extracted in 10 µl 1× homogenization buffer (containing
500 µg/mL Proteinase K), and genotyping was performed with the appropriated primers.
3.6. Western Blot Analysis
Liver homogenates were prepared from snap frozen liver tissue. Protein lysates were blotted and
probed with antibodies against HSC70 (sc-7298; Santa Cruz, CA, USA), STAT5A/B (rabbit polyclonal
antibody, epitope aa775-788 and STAT3 (#06-596; BD Biosciences, Franklin Lakes, NJ, USA).
4. Conclusions
In conclusion, we have generated and validated a new mouse strain harboring a conditional allele
for the Stat5a, Stat5b and Stat3 loci. This new mouse strain will serve as a valuable tool to address
the combined functions of STAT3 and STAT5A/B in tumorigenesis and other (patho)physiological
processes, expanding the research tools of the JAK/STAT scientific community.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1226/s1,
Figure S1: Schematic description of the Southern blot strategy presented in Figure 1B. Figure S2: Densitometric
quantification and uncropped Western blots related to the Figure 3C.
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